Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Barinthus Biotherapeutics plc.VACC · Entity 9597 | Chief Operating Officer | January 03, 2023 | February 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Barinthus Biotherapeutics plc.
Report date January 03, 2023 · Filed February 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2033-01-03 | Direct | 105,000 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 105,000 · Balance 105,000 F2: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Feb 23, 2023 16:54 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-23-024801 · tm237643-2_4seq1.xml · derivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Ordinary Shares · 105,000 shares Expires 2033-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 16:26 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 39,176 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-095142 · tm2224672-1_4seq1.xml · derivative · entry 7 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980 Underlying: Ordinary Shares · 39,176 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 16:26 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 25,000 | $7.07 | $176,707.50 |
DisclosureSEC source: 0001104659-22-095142 · tm2224672-1_4seq1.xml · nonDerivative · entry 5 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 - $7.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 16:26 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 14,176 | $5.69 | $80,688.37 |
DisclosureSEC source: 0001104659-22-095142 · tm2224672-1_4seq1.xml · nonDerivative · entry 4 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,075 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.46 - $5.93. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 16:26 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 39,176 | $0.00 | $15.67 |
DisclosureSEC source: 0001104659-22-095142 · tm2224672-1_4seq1.xml · nonDerivative · entry 3 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 16:26 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-095142 · tm2224672-1_4seq1.xml · derivative · entry 6 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,156 Underlying: Ordinary Shares · 450 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 16:26 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 450 | $4.78 | $2,152.22 |
DisclosureSEC source: 0001104659-22-095142 · tm2224672-1_4seq1.xml · nonDerivative · entry 2 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 - $4.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 16:26 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 450 | $0.00 | $0.18 |
DisclosureSEC source: 0001104659-22-095142 · tm2224672-1_4seq1.xml · nonDerivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 2,175 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-092960 · tm2223471-5_4seq1.xml · derivative · entry 6 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,606 Underlying: Ordinary Shares · 2,175 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 2,175 | $4.84 | $10,530.92 |
DisclosureSEC source: 0001104659-22-092960 · tm2223471-5_4seq1.xml · nonDerivative · entry 4 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.18 - $4.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 2,175 | $0.00 | $0.87 |
DisclosureSEC source: 0001104659-22-092960 · tm2223471-5_4seq1.xml · nonDerivative · entry 3 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 649 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-092960 · tm2223471-5_4seq1.xml · derivative · entry 5 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,781 Underlying: Ordinary Shares · 649 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 649 | $4.77 | $3,092.74 |
DisclosureSEC source: 0001104659-22-092960 · tm2223471-5_4seq1.xml · nonDerivative · entry 2 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 - $4.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 649 | $0.00 | $0.26 |
DisclosureSEC source: 0001104659-22-092960 · tm2223471-5_4seq1.xml · nonDerivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-092177 · tm2223471-3_4seq1.xml · derivative · entry 6 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,430 Underlying: Ordinary Shares · 2,200 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 2,200 | $4.78 | $10,513.14 |
DisclosureSEC source: 0001104659-22-092177 · tm2223471-3_4seq1.xml · nonDerivative · entry 4 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 - $4.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 2,200 | $0.00 | $0.88 |
DisclosureSEC source: 0001104659-22-092177 · tm2223471-3_4seq1.xml · nonDerivative · entry 3 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 5,350 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-092177 · tm2223471-3_4seq1.xml · derivative · entry 5 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,630 Underlying: Ordinary Shares · 5,350 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 5,350 | $4.76 | $25,463.33 |
DisclosureSEC source: 0001104659-22-092177 · tm2223471-3_4seq1.xml · nonDerivative · entry 2 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 - $4.76. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 5,350 | $0.00 | $2.14 |
DisclosureSEC source: 0001104659-22-092177 · tm2223471-3_4seq1.xml · nonDerivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 28, 2022 Filed Jul 15, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionShare Option (Right to Buy) · Derivative | 5 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-080209 · tm2221185-2_4seq1.xml · derivative · entry 3 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,980 Underlying: Ordinary Shares · 5 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. The exercise price of this option is GBP 0.000324 per share and has been converted from pounds sterling to U.S. dollars using an average exchange rate of $1.3269 to GBP 1.00 on December 31, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 28, 2022 Filed Jul 15, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 5 | $6.00 | $30.00 |
DisclosureSEC source: 0001104659-22-080209 · tm2221185-2_4seq1.xml · nonDerivative · entry 2 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 28, 2022 Filed Jul 15, 2022 16:06 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | Exercise / conversionOrdinary Shares | 5 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-080209 · tm2221185-2_4seq1.xml · nonDerivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 03, 2022 Filed Feb 11, 2022 19:53 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001104659-22-020822 · tm226469-3_4seq1.xml · derivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Ordinary Shares · 80,000 shares Expires 2032-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 16:27 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | PurchaseOrdinary Shares | 75 | $17.00 | $1,275.00 |
DisclosureSEC source: 0001104659-21-062427 · tm2115262-4_4seq1.xml · nonDerivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:22 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 97,335 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061218 · tm2114558-15_4seq1.xml · derivative · entry 2 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,335 Underlying: Ordinary Shares · 97,335 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:22 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 5,708 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061218 · tm2114558-15_4seq1.xml · derivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,708 Underlying: Ordinary Shares · 5,708 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.